(Q37079916)

18 August 2017

1 reference

title

Treatment strategies in myelodysplastic syndromes (English)

1 reference

18 August 2017

Ehab Atallah

1

1 reference

18 August 2017

Guillermo Garcia-Manero

series ordinal

2

1 reference

18 August 2017

publication date

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

208-216

1 reference

The myelodysplastic syndromes: a matter of life or death

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Bone marrow transplantation for myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

T cell‐mediated inhibition of erythropoiesis in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thalidomide for the treatment of patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thrombotic complications of myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701788122

10.1080/07357900701788122

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference